AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke


ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.

I'm interested

This study is NOT accepting healthy volunteers


Apixaban, Aspirin, Atrial Cardiopathy, Clinics and Surgery Center (CSC), Cryptogenic stroke, Ischemic stroke

Anna Brauch -
Benjamin Miller
Phase III
See this study on